11 unknown. 11 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Unknown 11 |
| Phase 1 | 4 | Unknown 4 |
| Phase 3 | 2 | Unknown 2 |
Follow Safety: new trials by email Literature Review of Safety trials Research Report on Safety
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer Tirolizumab+SOX/XELOX, SOX/XELOX - Locally Advanced Gastric Carcinoma, HER2 Negative | Phase 2 | Unknown | Lin Chen | 80 | 2023-10-01 | 2024-02-29 |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors Cadonilimab, Stereotactic body radiotherapy - Advanced Solid Tumor, Stereotactic Body Radiotherapy | Phase 1 / Phase 2 | Unknown | Peking University Third Hospital | 60 | 2023-06-21 | 2023-06-23 |
| A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2; - Immunogenicity, Safety | Phase 2 / Phase 3 | Unknown | Stemirna Therapeutics | 800 | 2023-06-20 | 2023-06-20 |
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 30 | 2023-01-10 | 2023-06-28 |
| A Phase Ic/IIb Study to Evaluate the Efficacy,Safety and Pharmacokinetics of HST in Patients With CHB Hepenofovir Fumarate Tablets - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 48 | 2022-11-10 | 2023-11-08 |
| PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer PD-L1 inhibitor - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2022-04-01 | 2022-04-13 |
| Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients Advixa (Adalimumab) - Pharmacokinetics, Safety | Phase 2 / Phase 3 | Unknown | Institute for Developing Science and Health Initiatives, Bangladesh | 200 | 2021-06-02 | 2022-07-07 |
| Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance Almonertinib combine with Pyrrolitinib - Safety | Phase 2 | Unknown | Sun Yat-sen University | 36 | 2020-12-31 | 2021-03-08 |
| Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC Tislelizumab 200 mg, Carboplatin AUC 5, pemetrexed 500mg/m2 - Tislelizumab, Safety | Phase 2 | Unknown | Hao Long | 100 | 2020-12-22 | 2022-02-17 |
| Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19 Nintedanib 150 MG, Placebo - COVID-19, Nintedanib | Phase 2 | Unknown | Huilan Zhang | 96 | 2020-04-02 | 2020-04-08 |
| Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients Umbilical cord blood infusion, Erythropoietin injection, Placebo umbilical cord blood infusion - Stroke, Umbilical Cord Blood | Phase 1 / Phase 2 | Unknown | Bundang CHA Hospital | 24 | 2019-05-02 | 2020-11-05 |
Arthritis, Rheumatoid (1) · COVID-19 (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Leukemia (1) · Lymphoma (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Stroke (1)
Immune System Diseases (2) · Arthritis (1) · Autoimmune Diseases (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Connective Tissue Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immunoproliferative Disorders (1) · Infections (1)
130-nm albumin-bound paclitaxel (1) · Adalimumab (1) · Carboplatin (1) · Erythropoietin (1) · Immune Checkpoint Inhibitors (1) · Paclitaxel (1) · Pemetrexed (1) · Radiosurgery (1) · Rehabilitation (1) · nintedanib (1) · tislelizumab (1)
Bundang CHA Hospital (1) · Hao Long (1) · Huilan Zhang (1) · Institute for Developing Science and Health Initiatives, Bangladesh (1) · Lin Chen (1) · Peking University Third Hospital (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Stemirna Therapeutics (1) · Sun Yat-sen University (1) · The Affiliated Hospital of Qingdao University (1) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (1)
China (6) · Bangladesh (1) · South Korea (1)
Hongqing Zhuang, M.D. (1) · Mayfong Mayxay, doctor (1) · MinYoung Kim, MD,PhD (1) · Xianmin G Song (1) · Xiaochun Zhang, Prof (1) · Zannat Kawser, M.Phil. (1)